AAM Statement on Avalere Medicare Analysis | Association for Accessible Medicines
Generic Prescription Drugs - Your Health. Our Commitment. #Take with Confidence

AAM Statement on Avalere Medicare Analysis

AAM Statement on Generic Drugs in Medicare Part D. Trends in Tier Structure and Placement, Avalere Health, May 22, 2018:

“In 2015, patients spent more than $6 billion in additional out-of-pocket costs on generic drugs compared to 2011. These increased out-of-pocket expenses on low-cost generics are being used by the plans to mask increases in branded drug prices.”

Avalere Health study funded by Association for Accessible Medicines.

ATTRIBUTE TO: Chip Davis, AAM President and CEO

Press Release

Read Avalere Report

 

MEDIA CONTACT:
Rachel Schwartz 
202.249.7147 (o)
202.251.8881 (c)

 

Association for Accessible Medicines

202.249.7100

Sign-up for Updates

Receive relevant industry news, event information and the latest resources on biosimilars and generic medicines.

Stay Connected

For the latest updates, follow us on social media.